Zimmer Buys Abbott: Difficult Times Ahead in Spine
Executive Summary
If spine is such a promising market, why did Abbott sell its spine business to Zimmer? The sale is a reflection of the transition period underway in the spine market, a transition born of a combination of the glut of small companies, the disappearance of large buyers, and also, some disappointments in some of spine's most promising technologies, And with that transition has come a perceptible loss of momentum in spine. For now that means depressed valuations on private financings for venture-backed spine companies and less-than-clear exits-an amazing turn around for an industry segment that just a couple of years ago looked strikingly different, certainly not the kind of spine industry Abbott thought it was buying into six years ago.
You may also be interested in...
NuVasive: Outpacing a Slowing Spine Market
For the past several years, NuVasive has been growing faster than its rivals in spine, thanks to its innovative XLIF procedure, a lateral approach to minimally-invasive spine surgery. But now the spine market overall has hit a wall. In a market no longer growing, can NuVasive continue to grow?
NuVasive: Outpacing a Slowing Spine Market
For the past several years, NuVasive has been growing faster than its rivals in spine, thanks to its innovative XLIF procedure, a lateral approach to minimally-invasive spine surgery. But now the spine market overall has hit a wall. In a market no longer growing, can NuVasive continue to grow?
Dealmaking in 2009: A Look Back and A Glance Ahead
This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.